New hope for liver cancer patients: 4-drug combo targets untreatable tumors
NCT ID NCT07230314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a powerful combination of treatments for people with liver cancer that cannot be surgically removed. It combines two local therapies (TACE and SBRT) with an immunotherapy drug and a targeted pill (donafenib) as the first treatment. The goal is to shrink tumors and control the disease. The study involves 34 adults aged 18-75 who have not had prior systemic therapy for their current cancer stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••